KURA · Kura Oncology, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-29 | Leoni Mollie |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares sold were acquired by the Reporting Person upon vesting of performance restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. This transaction was executed in multiple trades at prices ranging from $10.53 to $10.89. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
28,802 |
| 2026-09-29 | FORD KATHLEEN |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares sold were acquired by the Reporting Person upon vesting of performance restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026. This transaction was executed in multiple trades at prices ranging from $10.57 to $10.87. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
3,668 |
| 2026-09-29 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $10.55 to $10.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
15,430 |
| 2026-09-28 | DOYLE THOMAS JAMES |
SVP, Finance & Accounting |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares. Includes 1,868 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. |
Common Stock
|
4,607 |
| 2026-09-28 | FORD KATHLEEN |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares. |
Common Stock
|
6,906 |
| 2026-09-28 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on September 27, 2025. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. This transaction was executed in multiple trades at prices ranging from $10.40 to $10.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
8,000 |
| 2026-09-28 | Leoni Mollie |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares. |
Common Stock
|
12,448 |
| 2026-09-28 | Bair Teresa Brophy |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares. |
Common Stock
|
8,442 |
| 2026-09-28 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 9/27/25. |
Common Stock
|
9,020 |
| 2026-09-24 | Burrows Francis |
Chief Scientific Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option is fully vested. |
Stock Option (Right to Buy)
|
30,000 |
| 2026-09-24 | Burrows Francis |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $10.82 to $10.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
20,726 |
| 2026-09-24 | Burrows Francis |
Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability. Includes 629 shares acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. |
Common Stock
|
30,000 |
| 2026-09-08 | Fulk Jennifer |
CHIEF FINANCIAL OFFICER |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter. |
Option to purchase common stock
|
450,000 |
| 2026-08-24 | WILSON TROY EDWARD |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
(I)
|
100,000 |
| 2026-08-21 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
4,345 |
| 2026-08-19 | Bair Teresa Brophy |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares sold were acquired by the Reporting Person upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2026. This transaction was executed in multiple trades at prices ranging from $12.44 to $12.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
31,487 |
| 2026-08-17 | WILSON TROY EDWARD |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
This transaction was executed in multiple trades at prices ranging from $10.87 to $11.31. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
(I)
|
100,000 |
| 2026-06-18 | Leoni Mollie |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares sold were acquired by the Reporting Person upon vesting of restricted stock units and performance restricted stock units during the period from January 26, 2022 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. This transaction was executed in multiple trades at prices ranging from $9.56 to $9.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
84,929 |
| 2026-06-04 | Parks Diane L. |
Director |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
This option vests in full on the one year anniversary of the date of grant. |
Option to purchase common stock
|
35,000 |
| 2026-06-04 | Szela Mary T |
Director |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
This option vests in full on the one year anniversary of the date of grant. |
Option to purchase common stock
|
35,000 |
| 2026-06-04 | Hasnain Faheem |
Director, President & CEO |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
This option vests in full on the one year anniversary of the date of grant. |
Option to purchase common stock
|
35,000 |
| 2026-06-04 | Collins Helen Louise |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
This option vests in full on the one year anniversary of the date of grant. |
Option to purchase common stock
|
35,000 |
| 2026-06-04 | VASCONCELLES MICHAEL |
Director |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
This option vests in full on the one year anniversary of the date of grant. |
Option to purchase common stock
|
35,000 |
| 2026-06-04 | Malley Thomas |
Director |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
This option vests in full on the one year anniversary of the date of grant. |
Option to purchase common stock
|
35,000 |
| 2026-06-04 | SCHAFER CAROL |
Director |
Award↑
Filing footnotes — Option to purchase common stock (Direct)
This option vests in full on the one year anniversary of the date of grant. |
Option to purchase common stock
|
35,000 |
| 2026-05-21 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. |
Common Stock
|
10,000 |
| 2026-05-19 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. 678 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. |
Common Stock
|
339 |
| 2026-05-19 | FORD KATHLEEN |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2025. 2,257 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. This transaction was executed in multiple trades at prices ranging from $8.97 to $9.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
2,257 |
| 2026-05-18 | Bair Teresa Brophy |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. 2,256 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. This transaction was executed in multiple trades at prices ranging from $9.28 to $9.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
2,256 |
| 2026-03-23 | WILSON TROY EDWARD |
Director |
Convert↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents stock options exercised. This option is fully vested. |
Stock Option (Right to Buy)
|
6,103 |
| 2026-03-23 | WILSON TROY EDWARD |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
Represents stock options exercised. |
Common Stock
|
6,103 |
| 2026-03-18 | Malley Thomas |
Director |
Convert↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents stock options exercised. This option is fully vested. |
Stock Option (Right to Buy)
|
10,000 |
| 2026-03-18 | Malley Thomas |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
Represents stock options exercised. |
Common Stock
|
10,000 |
| 2026-01-27 | DOYLE THOMAS JAMES |
SVP, Finance & Accounting |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. |
Common Stock
|
1,114 |
| 2026-01-27 | Leoni Mollie |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. |
Common Stock
|
1,341 |
| 2026-01-27 | Bair Teresa Brophy |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. |
Common Stock
|
4,777 |
| 2026-01-27 | Bair Teresa Brophy |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. |
Common Stock
|
4,096 |
| 2026-01-27 | FORD KATHLEEN |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. |
Common Stock
|
1,813 |
| 2026-01-27 | DOYLE THOMAS JAMES |
SVP, Finance & Accounting |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. |
Common Stock
|
695 |
| 2026-01-27 | DOYLE THOMAS JAMES |
SVP, Finance & Accounting |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. |
Common Stock
|
2,226 |
| 2026-01-27 | DOYLE THOMAS JAMES |
SVP, Finance & Accounting |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. |
Common Stock
|
2,226 |
| 2026-01-27 | Leoni Mollie |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. |
Common Stock
|
3,655 |
| 2026-01-27 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. |
Common Stock
|
4,842 |
| 2026-01-27 | Powl Brian T. |
Chief Commercial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. |
Common Stock
|
1,572 |
| 2026-01-27 | Leoni Mollie |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. |
Common Stock
|
951 |
| 2026-01-27 | Leoni Mollie |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/24. |
Common Stock
|
2,233 |
| 2026-01-27 | Bair Teresa Brophy |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. |
Common Stock
|
2,335 |
| 2026-01-27 | Burrows Francis |
Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. |
Common Stock
|
1,311 |
| 2026-01-27 | DOYLE THOMAS JAMES |
SVP, Finance & Accounting |
Sell↓
Filing footnotes — Common Stock (Direct)
Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22. |
Common Stock
|
881 |
| 2026-01-02 | DOYLE THOMAS JAMES |
SVP, Finance & Accounting |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. Includes 802 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. |
Common Stock
|
21,250 |